NCT06875960RecruitingPhase 4
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
A Continuation Protocol for Deucravacitinib in Patients With Patients With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- First submitted
- 12 Mar 2025
- Start date
- 24 Feb 2026
- Primary completion date
- 31 Jan 2028
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Lupus (SLE)
- NCT number
- NCT06875960
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 35
- From 24 Feb 2026 to the primary completion date, 31 Jan 2028
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants must not have any disease or medical condition that, in the opinion of the physician, would make the subject unsuitable for this protocol, would interfere with the interpretation of subject safety or considered unsuitable by the physician for any other reason.
- Participants must not have any evidence of active Tuberculosis (TB).
Other
- Other protocol-defined Inclusion/Exclusion criteria apply.
Who the study is looking for
- Participants must have completed Study IM011074 or Study IM011132 through the protocol-required treatment period.
- Participants must be, based on the physician's medical judgement, likely to receive benefit from receiving treatment with deucravacitinib.
- Participants must have received IP within 60 days of enrollment. Exceptions may be granted based upon consultation with BMS.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Farmington | United States | Withdrawn |
| - Coordinator of this site? Confirm its status | Jackson | United States | Withdrawn |
| New York University School of Medicine Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| Oklahoma Medical Research Foundation Coordinator of this site? Confirm its status | Oklahoma City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.